On the question of the neuroleptic-induced metabolic syndrome. Study 2: fat distribution and specific hormonal parameters. Comparison between schizophrenic patients vulnerable and non-vulnerable to the metabolic syndrome

Trial Profile

On the question of the neuroleptic-induced metabolic syndrome. Study 2: fat distribution and specific hormonal parameters. Comparison between schizophrenic patients vulnerable and non-vulnerable to the metabolic syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Ziprasidone (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top